Select Publications
Byrd JC et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB
9011. Blood 2005;105(1):49-53. Abstract
Cortes JG et al. First report of the TOPS study: A randomized phase III trial of 400 mg vs 800 mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints. Proc European Haematology Association
2008;Abstract 402.
Faderl S et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101(9):3413-5. Abstract
Hillmen P et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25(35):5616-23. Abstract
Kantarjian H et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007;109(12):5143-50. Abstract
Kantarjian HM et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2003;101(2):473-5. Abstract
Keating MJ et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood 2002;99(10):3554-61. Abstract
Knauf WU et al. Bendamustine versus chlorambucil in treatment-naive patients with B-Cell chronic lymphocytic leukemia (B-CLL): Results of an International phase III study. Proc ASH 2007;Abstract 2043.
Lin TS et al. Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101. Proc ASH 2007;Abstract 755.
Roche Laboratories Inc. MabThera increases the time patients with the most common form of adult leukaemia live without their cancer progressing. Press release. January 25,
2008. Abstract
Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with indolent and mantle cell lymphomas — First interim results of a randomized phase III study of the StiL (Study Group Indolent
Lymphomas, Germany). Proc ASH 2007;Abstract 385.
| Table of Contents | Top of Page |
EDITOR
Neil Love, MD
INTERVIEWS
Steven D Gore, MD
- Select publications
Michael J Keating, MB, BS
- Select publications
William I Bensinger, MD
- Select publications
Fredrick B Hagemeister, MD
- Select publications
